MPM Asset Management LLC Lowers Stock Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX)

MPM Asset Management LLC lessened its stake in shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 24.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,683,707 shares of the company's stock after selling 558,929 shares during the quarter. Repare Therapeutics comprises approximately 1.8% of MPM Asset Management LLC's holdings, making the stock its 6th largest position. MPM Asset Management LLC owned about 3.96% of Repare Therapeutics worth $2,206,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Barclays PLC lifted its position in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company's stock worth $29,000 after purchasing an additional 7,800 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Repare Therapeutics by 204.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after purchasing an additional 23,127 shares during the last quarter. Vontobel Holding Ltd. lifted its position in shares of Repare Therapeutics by 45.8% during the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company's stock worth $46,000 after purchasing an additional 11,000 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in shares of Repare Therapeutics during the 4th quarter worth about $104,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Repare Therapeutics by 2,144,950.0% during the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock worth $112,000 after purchasing an additional 85,798 shares during the last quarter. Institutional investors own 85.09% of the company's stock.

Repare Therapeutics Stock Up 0.8%

Repare Therapeutics stock traded up $0.01 during trading hours on Friday, hitting $1.34. The stock had a trading volume of 181,449 shares, compared to its average volume of 260,582. The company has a 50-day moving average of $1.17 and a two-hundred day moving average of $1.68. The company has a market cap of $57.47 million, a PE ratio of -0.67 and a beta of 0.85. Repare Therapeutics Inc. has a fifty-two week low of $0.89 and a fifty-two week high of $4.29.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. As a group, analysts forecast that Repare Therapeutics Inc. will post -2.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their price objective on Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, March 7th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.